Verteporfin Photodynamic Therapy Combined with Intravitreal Ranibizumab for Polypoidal Choroidal Vasculopathy Controversy Concerning Long-Term Followup
Purpose. To show the long-term results of intravitreal ranibizumab combined with photodynamic therapy (PDT) for the treatment of polypoidal choroidal vasculopathy (PCV). Methods. We analyzed the progress of two patients for 36 and 58 months, respectively. We only used PDT for the treatment in the ar...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Case Reports in Medicine |
| Online Access: | http://dx.doi.org/10.1155/2012/897097 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556391685947392 |
|---|---|
| author | Maribel Fernández María Gil Francisco Gomez-Ulla Pablo Charlón |
| author_facet | Maribel Fernández María Gil Francisco Gomez-Ulla Pablo Charlón |
| author_sort | Maribel Fernández |
| collection | DOAJ |
| description | Purpose. To show the long-term results of intravitreal ranibizumab combined with
photodynamic therapy (PDT) for the treatment of polypoidal choroidal vasculopathy (PCV). Methods. We analyzed the progress of two patients for 36 and 58 months, respectively. We only
used PDT for the treatment in the area of the active PCV or “hot spot” evident on the
indocyanine green angiography (ICGA). The spot size was chosen so as to cover only the
active neovascular lesion. We combined intravitreal ranibizumab with PDT when PCV
remained active without visible polyps in ICGA or without a response to PDT. Conclusion. Administration, as required, of verteporfin photodynamic therapy combined
with intravitreal ranibizumab is an effective treatment for symptomatic polypoidal
choroidal vasculopathy. These data need to be confirmed in large, prospective, and controlled
clinical trials which are randomized and carried out over a long period. |
| format | Article |
| id | doaj-art-6bfc9abb9ffa4ea0bd4ac1f7f95bb336 |
| institution | Kabale University |
| issn | 1687-9627 1687-9635 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Medicine |
| spelling | doaj-art-6bfc9abb9ffa4ea0bd4ac1f7f95bb3362025-02-03T05:45:29ZengWileyCase Reports in Medicine1687-96271687-96352012-01-01201210.1155/2012/897097897097Verteporfin Photodynamic Therapy Combined with Intravitreal Ranibizumab for Polypoidal Choroidal Vasculopathy Controversy Concerning Long-Term FollowupMaribel Fernández0María Gil1Francisco Gomez-Ulla2Pablo Charlón3Department of Ophthalmology, University Hospital of Santiago de Compostela, Ramon Baltar S/N, 15706 Santiago de Compostela, SpainDepartment of Ophthalmology, University Hospital of Santiago de Compostela, Ramon Baltar S/N, 15706 Santiago de Compostela, SpainDepartment of Ophthalmology, University Hospital of Santiago de Compostela, Ramon Baltar S/N, 15706 Santiago de Compostela, SpainInstituto Oftalmológico Gómez-Ulla, Avenida de las Burgas 2, 15705 Santiago de Compostela, SpainPurpose. To show the long-term results of intravitreal ranibizumab combined with photodynamic therapy (PDT) for the treatment of polypoidal choroidal vasculopathy (PCV). Methods. We analyzed the progress of two patients for 36 and 58 months, respectively. We only used PDT for the treatment in the area of the active PCV or “hot spot” evident on the indocyanine green angiography (ICGA). The spot size was chosen so as to cover only the active neovascular lesion. We combined intravitreal ranibizumab with PDT when PCV remained active without visible polyps in ICGA or without a response to PDT. Conclusion. Administration, as required, of verteporfin photodynamic therapy combined with intravitreal ranibizumab is an effective treatment for symptomatic polypoidal choroidal vasculopathy. These data need to be confirmed in large, prospective, and controlled clinical trials which are randomized and carried out over a long period.http://dx.doi.org/10.1155/2012/897097 |
| spellingShingle | Maribel Fernández María Gil Francisco Gomez-Ulla Pablo Charlón Verteporfin Photodynamic Therapy Combined with Intravitreal Ranibizumab for Polypoidal Choroidal Vasculopathy Controversy Concerning Long-Term Followup Case Reports in Medicine |
| title | Verteporfin Photodynamic Therapy Combined with Intravitreal Ranibizumab for Polypoidal Choroidal Vasculopathy Controversy Concerning Long-Term Followup |
| title_full | Verteporfin Photodynamic Therapy Combined with Intravitreal Ranibizumab for Polypoidal Choroidal Vasculopathy Controversy Concerning Long-Term Followup |
| title_fullStr | Verteporfin Photodynamic Therapy Combined with Intravitreal Ranibizumab for Polypoidal Choroidal Vasculopathy Controversy Concerning Long-Term Followup |
| title_full_unstemmed | Verteporfin Photodynamic Therapy Combined with Intravitreal Ranibizumab for Polypoidal Choroidal Vasculopathy Controversy Concerning Long-Term Followup |
| title_short | Verteporfin Photodynamic Therapy Combined with Intravitreal Ranibizumab for Polypoidal Choroidal Vasculopathy Controversy Concerning Long-Term Followup |
| title_sort | verteporfin photodynamic therapy combined with intravitreal ranibizumab for polypoidal choroidal vasculopathy controversy concerning long term followup |
| url | http://dx.doi.org/10.1155/2012/897097 |
| work_keys_str_mv | AT maribelfernandez verteporfinphotodynamictherapycombinedwithintravitrealranibizumabforpolypoidalchoroidalvasculopathycontroversyconcerninglongtermfollowup AT mariagil verteporfinphotodynamictherapycombinedwithintravitrealranibizumabforpolypoidalchoroidalvasculopathycontroversyconcerninglongtermfollowup AT franciscogomezulla verteporfinphotodynamictherapycombinedwithintravitrealranibizumabforpolypoidalchoroidalvasculopathycontroversyconcerninglongtermfollowup AT pablocharlon verteporfinphotodynamictherapycombinedwithintravitrealranibizumabforpolypoidalchoroidalvasculopathycontroversyconcerninglongtermfollowup |